Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.

Also called NCT02542007

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 440 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02542007
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02542007. Randomized; no masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2017-05-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions
Acronym
RECOVERY
Condition
Coronary Arteriosclerosis
Intervention (Device)
OrbusNeich Combo stent™
Intervention (Device)
sirolimus-eluting stent system
Lead sponsor
OrbusNeich (class: industry)
Collaborator
CCRF Inc., Beijing, China (class: industry)
Collaborator
OrbusNeich Medical (Shenzhen), Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02542007
Content hash
a272d62ae85fe9e5c274a70b13228c75dcdf5d572bbb8908c32edc9d4df2f15e